- Home
- DSP vs PBYI Comparison
DSP vs PBYI Comparison
Compare DSP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- PBYI
- Stock Information
- Founded
- DSP 1999
- PBYI 2010
- Country
- DSP United States
- PBYI United States
- Employees
- DSP N/A
- PBYI N/A
- Industry
- DSP EDP Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- PBYI Health Care
- Exchange
- DSP Nasdaq
- PBYI Nasdaq
- Market Cap
- DSP 291.3M
- PBYI 153.2M
- IPO Year
- DSP 2021
- PBYI N/A
- Fundamental
- Price
- DSP $17.53
- PBYI $3.09
- Analyst Decision
- DSP Strong Buy
- PBYI Strong Buy
- Analyst Count
- DSP 7
- PBYI 1
- Target Price
- DSP $17.71
- PBYI $7.00
- AVG Volume (30 Days)
- DSP 198.1K
- PBYI 754.5K
- Earning Date
- DSP 03-03-2025
- PBYI 02-27-2025
- Dividend Yield
- DSP N/A
- PBYI N/A
- EPS Growth
- DSP N/A
- PBYI 492.79
- EPS
- DSP 0.08
- PBYI 0.47
- Revenue
- DSP $263,587,000.00
- PBYI $243,569,000.00
- Revenue This Year
- DSP $28.26
- PBYI N/A
- Revenue Next Year
- DSP $12.19
- PBYI N/A
- P/E Ratio
- DSP $230.51
- PBYI $6.63
- Revenue Growth
- DSP 23.73
- PBYI 6.30
- 52 Week Low
- DSP $6.50
- PBYI $2.23
- 52 Week High
- DSP $21.74
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- DSP 39.72
- PBYI 49.17
- Support Level
- DSP $16.78
- PBYI $2.92
- Resistance Level
- DSP $19.95
- PBYI $4.06
- Average True Range (ATR)
- DSP 0.88
- PBYI 0.29
- MACD
- DSP -0.40
- PBYI 0.01
- Stochastic Oscillator
- DSP 19.93
- PBYI 27.07
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.